SCHEMBL15420264

SCHEMBL15420264

CCS(=O)(=O)NC1CCOCC1COc1ccc(-n2cc(C)cn2)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT5 Q92993 1/20 0.39
HCRTR2 O43614 3/20 0.33
HCRTR1 O43613 2/20 0.33
PDE2A O00408 1/20 0.33
PDE10A Q9Y233 1/20 0.33
CCNT1 O60563 2/20 0.32
CDK1 P06493 2/20 0.32
CDK4 P11802 2/20 0.32
CCNB1 P14635 2/20 0.32
CCND1 P24385 2/20 0.32
CCNE1 P24864 2/20 0.32
CDK2 P24941 2/20 0.32
CCND3 P30281 2/20 0.32
CDK7 P50613 2/20 0.32
CDK9 P50750 2/20 0.32
CCNH P51946 2/20 0.32
MNAT1 P51948 2/20 0.32
CDK6 Q00534 2/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15441516 1.00 KAT5 (0.39) KAT5HCRTR2HCRTR1PDE2APDE10A
SCHEMBL15441821 0.92 SCN9A (0.38) KAT5PDE2APDE10ACCNT1CDK1
SCHEMBL15420330 0.92 SCN9A (0.38) KAT5PDE2APDE10ACCNT1CDK1
SCHEMBL15420173 0.90 HCRTR2 (0.36) KAT5HCRTR2HCRTR1MAPK8MAPK9
SCHEMBL15440891 0.90 HCRTR2 (0.36) KAT5HCRTR2HCRTR1MAPK8MAPK9
SCHEMBL15440879 0.90 HCRTR2 (0.36) KAT5HCRTR2HCRTR1MAPK8MAPK9
SCHEMBL15419964 0.87 KAT5 (0.38) KAT5HCRTR2HCRTR1ACACB
SCHEMBL15420102 0.87 KAT5 (0.38) KAT5HCRTR2HCRTR1ACACB
SCHEMBL15420129 0.87 KAT5 (0.38) KAT5HCRTR2HCRTR1ACACB
SCHEMBL12988822 0.85 KAT7 (0.37) KAT5HCRTR2HCRTR1PDE2APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 KAT5 2329/4885HCRTR2 383/4885HCRTR1 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.